Display options
Cite
Imafuku K, Yoshino K, Yamaguchi K, et al. Two Cases of Nivolumab Re-Administration after Pneumonitis as Immune-Related Adverse Events. Case Rep Oncol. 2017;10(1):296-300doi: 10.1159/000463379.
Imafuku, K., Yoshino, K., Yamaguchi, K., Tsuboi, S., Ohara, K., & Hata, H. (2017). Two Cases of Nivolumab Re-Administration after Pneumonitis as Immune-Related Adverse Events. Case reports in oncology, 10(1), 296-300. https://doi.org/10.1159/000463379
Imafuku, Keisuke, et al. "Two Cases of Nivolumab Re-Administration after Pneumonitis as Immune-Related Adverse Events." Case reports in oncology vol. 10,1 (2017): 296-300. doi: https://doi.org/10.1159/000463379
Imafuku K, Yoshino K, Yamaguchi K, Tsuboi S, Ohara K, Hata H. Two Cases of Nivolumab Re-Administration after Pneumonitis as Immune-Related Adverse Events. Case Rep Oncol. 2017 Apr 04;10(1):296-300. doi: 10.1159/000463379. eCollection 2017. PMID: 28512413; PMCID: PMC5422733.
Copy Download .nbib Format: NLM
Share it on

Case Rep Oncol. 2017 Apr 04;10(1):296-300. doi: 10.1159/000463379. eCollection 2017.

Two Cases of Nivolumab Re-Administration after Pneumonitis as Immune-Related Adverse Events.

Case reports in oncology

Keisuke Imafuku, Koji Yoshino, Kei Yamaguchi, Satoshi Tsuboi, Kuniaki Ohara, Hiroo Hata

Affiliations

  1. aTokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
  2. bDepartment of Dermatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.

PMID: 28512413 PMCID: PMC5422733 DOI: 10.1159/000463379

Abstract

Nivolumab is a recently approved medication for the treatment of unresectable malignant melanoma. Many immune-related adverse events (irAEs) associated with nivolumab have been reported, such as pneumonitis, hepatitis, dermatitis, and thyroiditis. Prednisolone can effectively treat irAEs. However, it is unclear how or if nivolumab should be administered to patients after they have experienced an irAE. Herein, we show 2 patients who underwent pneumonitis as irAE. Case 1 demonstrated a cryptogenic organizing pneumonia pattern in the CT scan and case 2 had a diffuse alveolar damage (DAD) pattern. Oral corticosteroids improved chest shadow of CT scan in both cases. However, when nivolumab was re-administrated, case 1 demonstrated no symptoms, but case 2 demonstrated pneumonia again. From our cases, it is difficult to re-administrate nivolumab for the patients with pneumonitis which shows a DAD pattern in CT, even if oral corticosteroids improve their symptoms.

Keywords: Cryptogenic organizing pneumonia; Diffuse alveolar damage; Immune-related adverse event; Nivolumab; Pneumonitis; Re-administration; Unresectable malignant melanoma

References

  1. N Engl J Med. 2012 Jun 28;366(26):2443-54 - PubMed
  2. J Clin Oncol. 2012 Jul 20;30(21):2691-7 - PubMed
  3. Transl Lung Cancer Res. 2015 Oct;4(5):560-75 - PubMed
  4. N Engl J Med. 2013 Jul 11;369(2):134-44 - PubMed
  5. N Engl J Med. 2015 Jan 22;372(4):320-30 - PubMed
  6. Oncologist. 2013 Jun;18(6):733-43 - PubMed
  7. Am J Respir Crit Care Med. 2002 Jan 15;165(2):277-304 - PubMed

Publication Types